Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US

Abstract

IMPORTANCE Guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) recommend intensive statin therapy and adding nonstatin therapy if low-density lipoprotein cholesterol (LDL-C) levels are 70 mg/dL or more. Compliance with guidelines is often low.OBJECTIVE To track LDL-C treatment patterns in the US over 2 years. DESIGN, SETTING, AND PARTICIPANTS GOULD is a prospective observational registry study involving multiple centers. Patients with ASCVD receiving any lipid-lowering therapy (LLT) were eligible. Between December 2016 and July 2018, patients were enrolled in 1 of 3 cohorts: (1) those currently receiving proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) and 2 groups not receiving PCSK9i drugs, with (2) LDL-C levels of 100 mg/dL or more or (3) LDL-C levels of 70 to 99 mg/dL. Patients had medical record reviews and telephone interviews every 6 months. Analysis was done on data collected as of October 5, 2020. MAIN OUTCOMES AND MEASURESThe primary outcome was the change in LLT use in 2 years. Secondary outcomes included the number of LDL-C measurements, LDL-C levels, and responses to structured physician and patient questionnaires over 2 years.RESULTS A total of 5006 patients were enrolled (mean [SD] age, 67.8 [9.9] years; 1985 women [39.7%]; 4312 White individuals [86.1%]). At 2 years, 885 (17.1%) had LLT intensification. In the cohorts with LDL-C levels of 100 mg/dL or more and 70 to 99 mg/dL, LLT intensification occurred in 403 (22.4%) and 383 (14.4%), respectively; statins were intensified in 115 (6.4%) and 168 (6.3%), ezetimibe added in 123 (6.8%) and 118 (4.5%), and PCSK9i added in 114 (6.3%) and 58 (2.2%), respectively. In the PCSK9i cohort, 508 of 554 (91.7%) were still taking PCSK9i at 2 years. Lipid panels were measured at least once over 2 years in 3768 patients (88.5%; PCSK9i cohort, 492 [96.1%]; LDL-C levels Ն100 mg/dL or more, 1294 [85.9%]; 70-99 mg/dL, 1982 [88.6%]). Levels of LDL-C fell from medians (interquartile ranges) of 120 (108-141) mg/dL to 95 (73-118) mg/dL in the cohort with LDL-C levels of 100 mg/dL or more, 82 (75-89) to 77 (65-90) mg/dL in the cohort with LDL-C levels of 70 to 99 mg/dL, and 67 (42-104) mg/dL to 67 (42-96) mg/dL in the PCSK9i cohort. Levels of LDL-C less than 70 mg/dL at 2 years were achieved by 308 patients (21.0%) and 758 patients (33.9%) in the cohorts with LDL-C levels of 100 mg/dL or more and 70 to 99 mg/dL, respectively, and 272 patients (52.4%) in the PCSK9i cohort. At 2 years, practice characteristics were associated with more LLT intensification (teaching vs nonteaching hospitals, 148 of 589 [25.1%] vs 600 of 3607 [16.6%]; lipid protocols or none, 359 of 1612 [22.3%] vs 389 of 2584 [15.1%]; cardiology, 452 of 2087 [21.7%] vs internal or family medicine, 204 of 1745 [11.7%] and other, 92 of 364 [25.3%]; all P < .001) and achievement of LDL-C less than 70 mg/dL (teaching vs nonteaching hospitals, 173 of 488 [35.5%] vs 823 of 2986 [27.6%]; lipid protocols vs none, 451 of 1411 [32.0%] vs 545 of 2063 [26.4%]; both P < .001; cardi...

Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study

“…The observed 92% persistence rate over 12 months is consistent with that in the 5-year international OSLER-1 open-label extension study, wherein the overall annualized rate of patients remaining on evolocumab was 93%, 14 as well as with the G etting to an Impr o ved U nderstanding of L ow-Density Lipoprotein-Cholesterol and D yslipedemia Management (GOULD) US real-world study, wherein 92% of patients were still taking a PCSK9 inhibitor at 2 years. 25 Lack of persistence to cardiovascular medications is associated with poor clinical outcomes, including hospitalization and mortality, especially in high-risk patients. International real-world evidence shows a lack of persistence to statin therapy, even among patients who undergo an ASCVD event, 26 , 27 , 28 which may be attributed to intolerance and fear of known side effects.…”

Sustained low‐density lipoprotein‐cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting

“…The 16% rate of patients achieving LDL-C <70 mg/dl was much lower than recent contemporary review of 230,000 patients with coronary heart disease 12,13 or 29% in Da Vinci study. [30][31][32] However, these studies were retrospective nature, and considered cross-sectional LDL-C levels obtained only at the baseline or short-term follow-up visit, which may magnify the rate of patients on target. It is estimated that up to 50% of patients do not maintain long-term lipid-lowering therapies even in secondary prevention.…”

Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes

“…However, despite the widely recognized causal role of LDL-c in determining atherosclerosis and MACE [ 11 ], and the availability of treatments allowing on more than 50% of reduction of LDL-c (i.e. proprotein convertase subtilisin/kexin type 9 inhibitors [PCSK9i] or high-intensity statins combined with ezetimibe), the improvement over time in achievement of LDL-c targets has been modest [ 5 , 9 , 10 ], leading to missed opportunity for cardiovascular prevention. The distance between guidelines and real-world observational data is commonly reported across studies from different countries and continents, and has led to the hypothesis of systematic problems leading to this unmet clinical need [ 1 ].…”